Identification
- Summary
-
Bocepreviris a hepatitis C virus NS3/4A protease inhibitor used in combination with other medications to treat chronic hepatitis C genotype 1 infection. Boceprevir is not indicated as monotherapy.
- 总的来说ic Name
- Boceprevir
- 药物Bank Accession Number
- DB08873
- Background
-
Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients7. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4Synthesis. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5BLabel. The barrier for develoment of resistance to NS3/4A inhibitors is lower than that of NS5B inhibitors, another class of DAAs5. Subtitutions at amino acid positions 155, 156, or 168 are known to confer resistance. The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself. Despite this disadvantage Boceprevir is still effective against HCV when paired withRibavirin,Peginterferon alfa-2a, andPeginterferon alfa-2b.
In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination withRibavirin,Peginterferon alfa-2a, andPeginterferon alfa-2bas first line therapy for Hepatitis C5. Boceprevir,Ribavirin,Peginterferon alfa-2a, andPeginterferon alfa-2bare used with the intent to cure, or achieve a sustained virologic response (SVR), after 48 weeks of daily therapy. SVR and eradication of HCV infection is associated with significant long-term health benefits including reduced liver-related damage, improved quality of life, reduced incidence of Hepatocellular Carcinoma, and reduced all-cause mortality6.
Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C. Approved in May 2011 by the FDA, Victrelis is indicated for the treatment of HCV genotype 1 in combination withRibavirin,Peginterferon alfa-2a, andPeginterferon alfa-2bLabel. Victrelis is no longer widely used as interferon-free therapies have been developed.
- Type
- Small Molecule
- Groups
- Approved, Withdrawn
- Structure
-
Structure for Boceprevir (DB08873)
- Weight
-
Average: 519.6767
Monoisotopic: 519.342069575 - Chemical Formula
- C27H45N5O5
- Synonyms
-
- Boceprevir
- External IDs
-
- EBP 520
- EBP-520
- SCH 503034
- SCH-503034
Pharmacology
- Indication
-
Boceprevir, when used in combination withRibavirin,Peginterferon alfa-2a, andPeginterferon alfa-2bis indicated for use in the treatment of chronic HCV genotype 1 infection in adultsLabel.
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Associated Conditions
- 禁忌症和黑箱警告
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support. - Pharmacodynamics
-
Boceprevir is classified as a direct-acting antiviral (DAA) and prevents viral replication in HCV genotype 1Label.
- Mechanism of action
-
Boceprevir is a NS3/4a protease inhibitor used to inhibit viral HCV replicationLabel. NS3/4a protease is an integral part of viral replication and mediates the cleavage the virally encoded polyprotein to mature proteins (NS4A, NS4B, NS5A and NS5B)Label. Boceprevir covalently but reversibly binds the serine (S139) resiude in the active site via a (α)-ketoamide functional group. This inhibits the proteolytic acitvity of the HCV 1a and 1b encoded enzyme.
Target Actions Organism ANS3/4A protein inhibitorHepatitis C Virus - Absorption
-
Boceprevir reaches peak plasma concentration 2 hours after administrationLabel. Absolute bioavailability has not been determined. When taken with food exposure increases up to 65%. In capsule, Boceprevir consists of two diaseromers in a 1:1 ratio. In plasma this ratio changes to 2:1 favoring the active diastereomer.
- Volume of distribution
-
The mean apparent volume of distribution for Bocepravir is 772 litres at steady stateLabel.
- Protein binding
-
Bocepravir is approximately 75% bound to human plasma proteins following a single doseLabel.
- Metabolism
-
Bocepravir is primarily metabolized via the aldo-ketoreductase-mediated pathway producing a diastereomeric mix of metabolites at a 4 fold greater exposure than the parent compoundLabel. Boceprevir also undergoes oxidative metabolism via CYP3A4/5, although to a lesser extent.
- Route of elimination
-
Boceprevir is mainly eliminated in the feces (79%) with a small amount eliminated in the urine (9%)Label. Approximately 8% and 3% is excreted as the parent compound in the feces and urine respectively.
- Half-life
-
Boceprevir has a mean half-life of elimination of 3.4 hoursLabel.
- Clearance
-
Boceprevir has a mean total body clearance of 161 liters per hourLabel.
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data. - Toxicity
-
The most commonly reported adverse reactions in adult subjects were fatigue, anemia, nausea, headache, and dysgeusia when Boceprevir was used in combination withRibavirinandPeginterferon alfa-2a/Peginterferon alfa-2bLabel.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- 药物InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
药物 Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The metabolism of 1,2-Benzodiazepine can be decreased when combined with Boceprevir. Abametapir The serum concentration of Boceprevir can be increased when it is combined with Abametapir. Abatacept The metabolism of Boceprevir can be increased when combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Boceprevir. Abiraterone The metabolism of Abiraterone can be decreased when combined with Boceprevir. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Boceprevir. Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Boceprevir. Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Boceprevir. Adalimumab The metabolism of Boceprevir can be increased when combined with Adalimumab. Adenovirus type 7 vaccine live The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Boceprevir. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
-
- Take with or without food. Food decreases drug exposure, but not to a clinically significant extent.
Products
-
药物product information from 10+ global regionsOur datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions. - Brand Name Prescription Products
-
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Victrelis Capsule 200 mg Oral Merck Ltd. 2011-08-02 2017-01-10 Canada 
Victrelis Capsule 200 mg Oral Merck Sharp Dohme Ltd 2016-09-08 2018-07-31 EU 
Victrelis Capsule 200 mg/1 Oral Merck Sharp & Dohme Limited 2011-05-13 2015-12-31 US 
Victrelis Capsule 200 mg Oral Merck Sharp Dohme Ltd 2016-09-08 2018-07-31 EU - Mixture Products
-
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Victrelis Triple Boceprevir(200 mg / cap)+Peginterferon alfa-2b(150 mcg / 0.5 mL)+Ribavirin(200 mg / cap) Capsule; Powder, for solution Oral; Subcutaneous Merck Ltd. 2011-08-16 2016-09-02 Canada Victrelis Triple Boceprevir(200 mg / cap)+Peginterferon alfa-2b(100 mcg / 0.5 mL)+Ribavirin(200 mg / cap) Capsule; Powder, for solution Oral; Subcutaneous Merck Ltd. 2011-08-16 2017-01-10 Canada Victrelis Triple Boceprevir(200 mg / cap)+Peginterferon alfa-2b(120 mcg / 0.5 mL)+Ribavirin(200 mg / cap) Capsule; Powder, for solution Oral; Subcutaneous Merck Ltd. 2011-08-16 2016-09-02 Canada Victrelis Triple Boceprevir(200 mg / cap)+Peginterferon alfa-2b(80 mcg / 0.5 mL)+Ribavirin(200 mg / cap) Capsule; Powder, for solution Oral; Subcutaneous Merck Ltd. 2011-08-16 2017-01-10 Canada
Categories
- ATC Codes
- J05AP03 — Boceprevir
- 药物Categories
-
- Amino Acids
- Amino Acids, Cyclic
- Amino Acids, Peptides, and Proteins
- Antiinfectives for Systemic Use
- Antiviral Agents
- Antivirals for Systemic Use
- Antivirals for treatment of HCV infections
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (strong)
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 CYP3A5 Inhibitors
- Cytochrome P-450 CYP3A5 Inhibitors (strong)
- Cytochrome P-450 CYP3A5 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- 细胞色素p - 450基质
- Direct Acting Antivirals
- Enzyme Inhibitors
- HCV NS3/4A Protease Inhibitors
- Imino Acids
- NS3/4A Protease Inhibitors
- P-glycoprotein inhibitors
- Protease Inhibitors
- Chemical TaxonomyProvided byClassyfire
-
- Description
- This compound belongs to the class of organic compounds known as hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta) linked to each other through a peptide bond.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Peptidomimetics
- Sub Class
- Hybrid peptides
- Direct Parent
- Hybrid peptides
- Alternative Parents
- Dipeptides/Valine and derivatives/N-carbamoyl-alpha amino acids and derivatives/Alpha amino acid amides/Piperidinecarboxamides/N-acylpiperidines/Pyrrolidinecarboxamides/N-acylpyrrolidines/Fatty amides/Tertiary carboxylic acid amides show 9 more
- Substituents
- 2-piperidinecarboxamide/Aliphatic heteropolycyclic compound/Alpha-amino acid amide/Alpha-amino acid or derivatives/Alpha-dipeptide/Azacycle/Carbonic acid derivative/Carbonyl group/Carboxamide group/Carboxylic acid derivative show 25 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- ureas, tripeptide (CHEBI:68621)
- Affected organisms
-
- Hepatitis C Virus
Chemical Identifiers
- UNII
- 89BT58KELH
- CAS number
- 394730-60-0
- InChI Key
- LHHCSNFAOIFYRV-DOVBMPENSA-N
- InChI
-
InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
- IUPAC Name
-
3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide
- SMILES
-
[H][C@]12CN([C@H](C(=O)NC(CC3CCC3)C(=O)C(N)=O)[C@@]1([H])C2(C)C)C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C
References
- Synthesis Reference
-
李道,James Lalonde,杰克梁,本杰明Mijts,Roger Sheldon, George S.K. Wong, Aleksey Zaks, "Substantially Stereomerically Pure Fused Bicyclic Proline Compounds and Processes for Preparing Boceprevir." U.S. Patent US20120289709, issued November 15, 2012.
US20120289709 - 总的来说al References
-
- Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. [Article]
- Treitel M, Marbury T, Preston RA, Triantafyllou I, Feely W, O'Mara E, Kasserra C, Gupta S, Hughes EA: Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012 Sep 1;51(9):619-28. doi: 10.2165/11633440-000000000-00000. [Article]
- Wilby KJ, Partovi N, Ford JA, Greanya E, Yoshida EM: Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol. 2012 Apr;26(4):205-10. [Article]
- Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas F, Hart A, Hesk D, Ingravallo P, Jiang C, Kong R, Lu J, Pichardo J, Prongay A, Skelton A, Tong X, Venkatraman S, Xia E, Girijavallabhan V, Njoroge FG: SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother. 2006 Mar;50(3):1013-20. [Article]
- Bagaglio S, Uberti-Foppa C, Morsica G: Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. Drugs. 2017 May 12. doi: 10.1007/s40265-017-0753-x. [Article]
- Myers RP, Shah H, Burak KW, Cooper C, Feld JJ: An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13. [Article]
- American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance. http://hcvguidelines.org. Accessed June 12, 2017. [Link]
- External Links
-
- KEGG Drug
- D08876
- PubChem Compound
- 10324367
- PubChem Substance
- 175427127
- ChemSpider
- 8499830
- BindingDB
- 12311
- 1102129
- ChEBI
- 68621
- ChEMBL
- CHEMBL218394
- PharmGKB
- PA165948902
- PDBe Ligand
- HU5
- RxList
- RxList Drug Page
- 药物s.com
- 药物s.com Drug Page
- Wikipedia
- Boceprevir
- FDA label
-
Download (403 KB)
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Phase Status Purpose Conditions Count 4 Completed Treatment Chronic Hepatitis C Virus (HCV) Infection 1 4 Completed Treatment Chronic Hepatitis C Virus (HCV) Infection/Human Immunodeficiency Virus (HIV) Infections 1 4 Completed Treatment Hepatitis C Virus (HCV) Infection 1 4 Terminated Treatment Hepatitis/Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) 1 4 Unknown Status Treatment Chronic Hepatitis C Virus (HCV) Infection/End Stage Renal Disease (ESRD) 1 4 Withdrawn Treatment Hepatitis C Virus (HCV) Infection 1 3 Completed Treatment Chronic Hepatitis C Genotype 1 1 3 Completed Treatment Chronic Hepatitis C Virus (HCV) Infection 9 3 Completed Treatment Co-Infection/Hepatitis C Virus (HCV) Infection/Human Immunodeficiency Virus (HIV) Infections 1 3 Completed Treatment Hepatitis C Virus (HCV) Infection 1
Pharmacoeconomics
- Manufacturers
-
Not Available
- Packagers
-
Not Available
- Dosage Forms
-
Form Route Strength Capsule Oral Capsule Oral 200 mg/1 Capsule Oral 200 mg Capsule, coated Oral 200 mg Capsule; powder, for solution Oral; Subcutaneous - Prices
- Not Available
- Patents
-
Patent Number Pediatric Extension Approved Expires (estimated) Region US7772178 No 2010-08-10 2027-11-11 US US8119602 No 2012-02-21 2027-03-17 US USRE43298 No 2012-04-03 2022-02-22 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
-
Property Value Source Water Solubility 0.0234 mg/mL ALOGPS logP 1.93 ALOGPS logP 1.78 ChemAxon logS -4.4 ALOGPS pKa (Strongest Acidic) 12.44 ChemAxon pKa (Strongest Basic) -0.91 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 150.7 Å2 ChemAxon Rotatable Bond Count 10 ChemAxon Refractivity 138.2 m3·mol-1 ChemAxon Polarizability 56.79 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
-
Property Value Probability Human Intestinal Absorption + 0.6781 Blood Brain Barrier - 0.8805 Caco-2 permeable - 0.6532 P-glycoprotein substrate Substrate 0.8394 P-glycoprotein inhibitor I Inhibitor 0.671 P-glycoprotein inhibitor II Inhibitor 0.6377 Renal organic cation transporter Non-inhibitor 0.8188 CYP450 2C9 substrate Non-substrate 0.7965 CYP450 2D6 substrate Non-substrate 0.7996 CYP450 3A4 substrate Substrate 0.621 CYP450 1A2 substrate Non-inhibitor 0.7987 CYP450 2C9 inhibitor Non-inhibitor 0.7265 CYP450 2D6 inhibitor Non-inhibitor 0.87 CYP450 2C19 inhibitor Non-inhibitor 0.6908 CYP450 3A4 inhibitor Non-inhibitor 0.9659 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8434 Ames test Non AMES toxic 0.662 Carcinogenicity Non-carcinogens 0.8555 Biodegradation Ready biodegradable 0.5913 Rat acute toxicity 2.6263 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9828 hERG inhibition (predictor II) Non-inhibitor 0.7092
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
-
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
insights and accelerate drug research.
- Kind
- Protein
- Organism
- Hepatitis C Virus
- Pharmacological action
-
Yes
- Actions
-
Inhibitor
- 总的来说al Function
- Serine-type peptidase activity
- Specific Function
- Not Available
- Gene Name
- NS3/4A
- Uniprot ID
- B0B3C9
- Uniprot Name
- Genome polyprotein
- 分子量
- 72789.28 Da
References
- Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA: Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol. 2013 Jul 19;8(7):1469-78. doi: 10.1021/cb400100g. Epub 2013 May 1. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
-
Unknown
- Actions
-
SubstrateInhibitor
- 总的来说al Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- 分子量
- 57342.67 Da
References
- Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. [Article]
- Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N: A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012 Mar-Apr;11(2):179-85. [Article]
- Hulskotte EG, Feng HP, Xuan F, Gupta S, van Zutven MG, O'Mara E, Wagner JA, Butterton JR: Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother. 2013 Jun;57(6):2582-8. doi: 10.1128/AAC.02347-12. Epub 2013 Mar 25. [Article]
- FDA Approved Drug Products: VICTRELIS (boceprevir) Capsules [Link]
- FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
- Boceprevir FDA label [File]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
-
Unknown
- Actions
-
SubstrateInhibitor
- 总的来说al Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- 分子量
- 57108.065 Da
References
- Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. [Article]
- Hulskotte E,古普塔年代,宣F,范Zutven M O ' maraE, Feng HP, Wagner J, Butterton J: Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 2012 Nov;56(5):1622-30. doi: 10.1002/hep.25831. Epub 2012 Oct 14. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
-
Unknown
- Actions
-
Inhibitor
- Curator comments
- Based on the findings of in vitro studies, boceprevir has the potential to inhibit P-gp; however, it had limited p-glycoprotein inhibitory potential at clinically relevant concentrations in a drug interaction study.
- 总的来说al Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- 分子量
- 141477.255 Da
References
- Kiser JJ, Flexner C: Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49. doi: 10.1146/annurev-pharmtox-011112-140254. Epub 2012 Nov 5. [Article]
药物created at May 12, 2013 04:45 / Updated at February 21, 2021 18:52